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HPA AXIS ACTIVITY IN PATIENTS WITH PANIC
DISORDER: REVIEW AND SYNTHESIS OF FOUR STUDIES
James L. Abelson, M.D., Ph.D., Samir Khan, Ph.D., Israel Liberzon, M.D., and Elizabeth A. Young, M.D.
Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis may play a
role in panic disorder. HPA studies in patients with panic disorder, however, have
produced inconsistent results. Seeking to understand the inconsistencies, we
reexamined endocrine data from four studies of patients with panic disorder,
in light of animal data highlighting the salience of novelty, control, and social
support to HPA axis activity. Patients with panic disorder were studied (1) at rest
over a full circadian cycle, (2) before and after activation by a panicogenic
respiratory stimulant (doxapram) that does not directly stimulate the HPA axis,
and (3) before and after a cholecystokinin B (CCK-B) agonist that is panicogenic
and does directly stimulate the HPA axis. Patients with panic disorder had
elevated overnight cortisol levels, which correlated with sleep disruption. ACTH
and cortisol levels were higher in a challenge paradigm (doxapram) than in a
resting state study, and paradigm-related ACTH secretion was exaggerated in
patients with panic disorder. Panic itself could be elicited without HPA axis
activation. Patients with panic disorder showed an exaggerated ACTH response
to pentagastrin stimulation, but this response was normalized by prior exposure
to the experimental context or psychological preparation to reduce novelty and
enhance sense of control. Novelty is one of a number of contextual cues known
from animal work to activate the HPA axis. The HPA axis abnormalities seen
in patients with panic disorder in the four experiments reviewed here might all
be due to exaggerated HPA axis reactivity to novelty cues. Most of the published
panic/HPA literature is consistent with the hypothesis that HPA axis
dysregulation in panic is due to hypersensitivity to contextual cues. This
hypothesis requires experimental testing. Depression and Anxiety 24:66–76,
2007. Published 2006 Wiley-Liss, Inc.
INTRODUCTION
Hypothalamic–pituitary–adrenal (HPA) axis activity
has been intensely investigated in patients with
depression and anxiety disorders for decades. The
HPA axis is a complex neuroendocrine ‘‘stress’’ system
involved in biobehavioral adaptation to challenge and
change. Psychiatric interest in it is not surprising given
known interactions between stress, anxiety and depres-
sion. However, meaningful psychiatric study of it
requires careful attention to the system’s complexities.
It has an intrinsic circadian rhythm, producing high
‘‘stress hormone’’ levels during the transition from
sleep to activity and lower levels as the sleep phase
again approaches, likely playing a role in entraining
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activity to the dark–light cycle. It also shows ultradian
rhythms due to a pulsatile secretion pattern that can be
entrained by stress exposure, creating acute reactivity
to particular types of stressors. It is regulated by
multiple feedback loops that prevent excessive HPA
activity, which is metabolically costly and potentially
damaging. A variety of probes have been used to study
this system in humans, variously tapping its basal
activity and circadian rhythm, its acute reactivity, or its
feedback sensitivity. To capture its biological rhythms
at basal state, frequent sampling over an extended
period is needed. Pharmacological probes [corticotro-
pin-releasing hormone (CRH), dexamethasone, metyr-
apone] are useful in assessing central drive and
feedback inhibition. Acute reactivity can be captured
using various laboratory or naturalistic stressor models.
HPA dysregulation was reported decades ago in
patients with major depressive disorder [MDD; Carroll
et al., 1981], and it is now clear that it may play an
important role in the pathophysiology of depression
[Young et al., 2003]. There is also considerable evidence
for HPA axis dysregulation in posttraumatic stress
disorder (PTSD) and some suggestion that this system
may play a role in its pathophysiology [Yehuda, 2002].
For example, the dexamethasone suppression test (DST)
has revealed abnormal escape from suppression in
patients with MDD [Carroll et al., 1981], suggesting
central overdrive of the HPA axis in this disorder, and
hypersuppression in PTSD, suggesting enhanced feed-
back inhibition in these patients [Yehuda et al., 1993].
Panic disorder, a common anxiety disorder often
associated with depression and PTSD, is responsive to
similar medications. Given these associations, it is
reasonable to expect HPA axis dysregulation in this
disorder as well, and it has been fairly extensively
studied. However, results have been strikingly incon-
sistent. Understanding these inconsistencies might
deepen understanding of both panic disorder and the
HPA axis.
Baseline or basal state activity within the HPA axis
is sometimes reported as elevated and sometimes as
normal in patients with panic disorder. Elevations have
been reported at ‘‘baseline’’ before a pharmacological
challenge [Roy-Byrne et al., 1986], but levels appear
normal when the baseline period is more extended
[Holsboer et al., 1987]. Patients with uncomplicated
panic have normal ‘‘resting’’ cortisol levels [Kathol
et al., 1988; Uhde et al., 1988], but resting state
elevations have also been reported [Goldstein et al.,
1987]. In a 24-hour ‘‘basal state’’ study with frequent
sampling, patients with panic disorder had normal
daytime cortisol levels but some elevation overnight
[Abelson and Curtis, 1996a].
Pharmacological probes of central drive and feed-
back inhibition have also produced inconclusive results
in patients with panic disorder. DST studies have not
demonstrated clear escape or hypersuppression [Curtis
et al., 1982; Goldstein et al., 1987; Lieberman et al.,
1983; Poland et al., 1985; Sheehan et al., 1983], though
DST results have not been entirely normal in panic
[Coryell and Noyes, 1988; Coryell et al., 1989;
Westberg et al., 1991]. Abnormalities seen have not
been linked to anxiety or panic symptoms, but they
have predicted relapse risk and long-term disability
[Coryell et al., 1989, 1991]. CRH challenge has
revealed blunted ACTH responses in two reports,
one with elevated baseline cortisol [Roy-Byrne et al.,
1986] and the other with normal baseline cortisol
[Holsboer et al., 1987], but both normal [Brambilla
et al., 1992; Rapaport et al., 1989] and enhanced
ACTH responses to CRH have also been seen [Curtis
et al., 1997; Schreiber et al., 1996].
Acute HPA axis reactivity has primarily been studied
in panic in the context of laboratory panic models.
Surprisingly, panicogenic stimuli (e.g., caffeine, sodium
lactate, CO2) can acutely trigger panic without a
concomitant increase in cortisol release [Hollander
et al., 1989; Levin et al., 1987; Liebowitz et al., 1985;
Peskind et al., 1998; Seier et al., 1997; Sinha et al.,
1999; van Duinen et al., 2004] or without cortisol
activation that is significantly different from healthy
controls [Charney et al., 1985]. However, cortisol
release by some of these laboratory panicogens has
occasionally been reported [Argyropoulos et al., 2002;
Charney et al., 1987; Woods et al., 1988]. There are
also some panicogens [e.g., cholecystokinin B (CCK-B)
agonists] that can activate the HPA axis by direct
pharmacological effect that is independent of panic
induction [Abelson et al., 2005]. Spontaneous or
natural panic attacks can occur without HPA axis
activation [Cameron et al., 1987; Woods et al., 1987],
though there is also evidence that cortisol levels are
higher during real-life panic than they are 24 hours
later, when an attack is not occurring [Bandelow et al.,
2000a]. There are very few data available regarding
HPA reactivity to other types of stressors in patients
with panic disorder.
A variety of methodological issues likely contribute to
the inconsistencies in this panic–HPA literature, but
there are also potentially clarifying clues in the basic
science literature on psychological factors that modulate
this system. Novelty is one factor that robustly activates
the HPA axis. Even benign increments in environmental
novelty can evoke sustained release of cortisol in animals
[Hennessy et al., 1995]. Social separation can also
acutely activate the HPA axis, whereas social support
can buffer the activating effects of other types of
challenge [Levine, 1992, 2000]. Control over a challenge
or perceived threat can also modulate the HPA axis
response to it [Weiss, 1968]. Unacknowledged or
unnoticed paradigm differences in novelty exposure,
social support, or perceived control could thus con-
tribute to differing results across studies done in
different centers, even when basic methodologies are
similar. Differences in sensitivity to any of these factors
could also contribute to group differences within studies.
We have recently reexamined our own previously
published data on HPA axis activity in patients with
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panic disorder, to explore the hypothesis that HPA axis
abnormalities in panic could be due to sensitivity to
contextual cues such as novelty or lack of control.
We present the results of that reexamination below. We
obtained the data utilizing four different paradigms: (1)
a ‘‘basal state’’ study over a full circadian cycle, (2) CRH
infusion, (3) doxapram challenge (respiratory stimulant
and panicogen without direct HPA effects), and (4)
pentagastrin challenge (CCK-B agonist and panicogen
that directly activates the HPA axis). We summarize
shared experimental methodology, then examine each
study separately, presenting a brief review of the design
and results, followed by interpretive commentary
related to the hypothesis. We then discuss the overall
results and reexamine inconsistencies in the panic–
HPA literature in light of our findings.
METHODS
Subjects: In all studies, subjects were 18–42 years of
age, healthy, with no current drug or alcohol abuse,
limited tobacco use, and within 725 pounds of normal
body weight. Females were premenopausal, not on oral
contraceptives, and were studied within 10 days of
menses onset. All subjects were administered the
Structured Clinical Interview for DSM-IV (SCID).
Patients met DSM-III-R or DSM-IV criteria for panic
disorder, with or without agoraphobia. Control
subjects who had no current psychiatric disorder and
no first-degree relatives with an affective or anxiety
disorder were age and sex matched to each patient.
Sampling and assays: Intravenous access, kept open
with a normal saline drip, was established in an arm
vein 1–2 hours before sampling began (except in the
24-hour study). Blood was drawn into vacuum tubes
containing heparin or ethylenediaminetetraacetic acid
(EDTA), and kept on ice until centrifuged. Plasma was
stored at 701C. We assayed cortisol using the Coat-
A-Count assay from Diagnostic Products Corporation
(Los Angeles, CA), and ACTH using the Allegro HS
IRMA from Nichols Institute (San Juan Capistrano,
CA). Sensitivities were approximately 6 pg/ml for
ACTH and 0.2 mg/dl for cortisol. Coefficients of
variation were generally less than 10%. Patient–control
dyads were always run in the same assay.
BASAL STATE/CRH STUDY
Design. Blood samples were drawn every 15 min-
utes over 24 hours, beginning at 6 P.M., in 12 healthy
subjects and 20 patients with panic disorder [Abelson
and Curtis, 1996a]. At 6 P.M. on day 2 a CRH test was
conducted, with baseline samples drawn every 5 min-
utes for 15 minutes, followed by intravenous injection
of CRH (1 mg/kg) and additional blood sampling (1 5,
15, 30, 60, 90, 120 minutes; Curtis et al., 1997].
Results. Cortisol levels in panic patients were
significantly elevated relative to controls overnight
(midnight to 6 A.M., Po.05), but not during the
daytime. This elevation was primarily accounted for
by a subset of six clinic-recruited patients who had
significantly higher 24-hour cortisol than controls
(Po.01) and than the 14 advertisement-recruited
patients (P 5.03). The clinic-recruited patients were
significantly more disabled (on the Sheehan Disability
Scale) than the advertisement-recruited patients
(Po.05), but the groups did not differ significantly
on any other illness severity measure. Cortisol eleva-
tions were significantly predicted by sampling-related
sleep disruption, defined as shorter duration of unin-
terrupted sleep as recorded in nurses’ sampling logs
[r 5 .5, Po.05; Abelson and Curtis, 1996a]. Cortisol
before treatment, but not illness severity, predicted
total, functional disability at 2-year follow-up [r 5 .7,
P 5.002; Abelson and Curtis, 1996b].
In the CRH test, there was a significant diagnosis
 time interaction (P 5.0003) for ACTH, due to an
earlier and somewhat higher peak ACTH level in
patients than in controls. The patients did not differ
significantly from controls in peak or total ACTH
response to CRH. Their baseline cortisol and ACTH
levels were also normal [Curtis et al., 1997].
Commentary. The correlation between sleep dis-
ruption and cortisol levels in our subjects may reflect
the normal linkage between nocturnal awakenings and
cortisol release [Leproult et al., 1997]. It is possible
that some patients—particularly the more disabled,
clinic-recruited subset—are more sensitive to environ-
mental stimuli than other patients and controls, both
acutely and chronically. Such sensitivity might under-
mine sleep continuity and produce higher nocturnal
cortisol levels. Cortisol elevations were indirectly
linked to functional disability at time of initial study
(the clinic-recruited patients were more disabled and
had higher cortisol levels) and predicted continuing
disability 2 years later, independently of panic fre-
quency or intensity. Hypersensitivity to environmental
cues, reflected in novelty-associated cortisol elevations,
may be a trait factor that disrupts sleep in the novel
laboratory setting and links similar levels of panic to
higher levels of functional disruption over time.
This same factor could create blunted ACTH
responses to CRH in some contexts, because novelty
sensitivity could elevate prechallenge cortisol levels,
which could in turn reduce post-CRH ACTH due
to feedback inhibition, as has been seen in some panic
studies [Roy-Byrne et al., 1986]. In our experiment,
however, the CRH challenge followed 24 hours of
‘‘accommodation,’’ leading to normal pre-CRH corti-
sol levels in the panic patients, and their ACTH
responses to CRH were not blunted.
DOXAPRAM STUDY
Design. Subjects were studied in a single session
divided into three phases—a 5-minute accommodation
period, a 15-minute placebo injection phase, and a
30-minute doxapram (0.5 mg/kg intravenously)
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injection phase. Samples were obtained from the
beginning of accommodation until 24 minutes post-
doxapram. Half of the subjects in each group received a
cognitive intervention prior to accommodation [Abel-
son et al., 1996].
Cognitive Intervention. Patients and their
matched controls were randomly assigned to receive
either standard instructions (SI) or a 9-minute cogni-
tive intervention (CI) designed to reduce the stressful-
ness of the experimental procedures. The CI included
the following components: (1) a more detailed descrip-
tion of expectable responses (to reduce novelty);
(2) coaching to attribute these responses to normal
reactions to doxapram rather than to anything danger-
ous (to facilitate ‘‘cognitive coping’’); and (3) informa-
tion suggesting that subjects could control exposure
to doxapram (if they needed to) by using an infusion
pump at their bedside.
Results. Doxapram stimulated hyperventilation
and physical symptoms in all subjects and panic attacks
in patients with panic disorder, but these effects were
not associated with significant cortisol release. Patients
had marginally higher cortisol levels than controls
(P 5.06) but did not differ from controls in cortisol
response to doxapram or in CI effects on cortisol. The
CI significantly altered the pattern of cortisol release in
all subjects combined (time  instruction interaction,
P 5.02). With the CI, baseline levels were slightly
higher and response to doxapram was lower (Fig. 1).
Subject selection criteria and patient characteristics
were identical between the basal state study described
earlier and this doxapram challenge study. To allow a
rough comparison of cortisol levels across experimental
paradigms, means for the combined patient–control
group from the basal state study are also included in
Figure 1, using only those time points that corre-
sponded to the exact time that samples were drawn in
the doxapram study. As can be seen, cortisol levels were
substantially higher in the challenge paradigm than in
the resting state paradigm.
There was no ACTH response associated with
doxapram-induced panic attacks. Patients with panic
disorder showed a significant elevation in ACTH levels
relative to controls throughout the challenge study
(P 5.02). At corresponding time points in the basal
state study, patients with panic disorder and controls
had identical ACTH levels [Abelson and Curtis,
1996a]. These data are shown in Figure 2.
Commentary. Dramatic physiological and emo-
tional activation occurred in response to doxapram,
without meaningful cortisol release. However, cortisol
secretion patterns were significantly altered by a brief
cognitive manipulation of specific psychological factors
(novelty, control, coping). Cortisol levels also appear
sensitive to the nature of the experimental paradigm,
with higher levels seen in a challenge study than after
prolonged stay in a basal state study. The ACTH data
support and extend the cortisol results, confirming that
doxapram-induced panic is not associated with HPA
axis activation, but showing that patients with panic
disorder do demonstrate an abnormal activation of the
HPA axis in the context of a challenge paradigm. This
abnormal activation is not present at a corresponding
time of day in the context of a nonchallenge, resting
state paradigm. It would thus appear that the patients
with panic disorder are psychologically hypersensitive
to an aspect of the experimental context (challenge)
that is salient to the HPA axis.
PENTAGASTRIN STUDY 1
Design. Cortisol and ACTH were measured
before (30 and 2 minutes) and after intravenous
Cognitive intervention group (n = 13)
Standard introduction group (n = 14)

























Figure 1. Mean cortisol levels before and after doxapram, in
combined groups of patients with panic disorder and controls,
with and without cognitive preparation. Levels for a comparable
group in a basal state are included for comparison.























Figure 2. ACTH levels (M7SE) in panic patients and controls,
before and after doxapram, compared to similar patient and
control subjects from a 24-hour basal state study.
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injection of placebo or pentagastrin (0.6 mg/kg).
Postinjection samples were obtained at 13, 5, 10, 20,
30, 45, and 60 minutes. This experiment was conducted
in two phases. In Phase 1, five patients and five controls
received pentagastrin during a single research visit.
In Phase 2, an additional five patients and five controls
received placebo on a first visit and pentagastrin on a
second visit. In Phase 1, all subjects were told that they
would receive pentagastrin. In Phase 2, subjects were
told that they might receive pentagastrin or placebo on
either visit, and could receive pentagastrin twice,
placebo twice, or one of each in either order. All visits
were identically structured and included a 1- to 112-hour
accommodation period prior to initiation of sampling
[Abelson et al., 1994].
Results. Data are shown in Figure 3. Patients had
greater post-pentagastrin ACTH secretion than con-
trols in Phase 1 (Po.05); but their post-pentagastrin
ACTH secretion was identical to controls in Phase 2.
Patients were more sensitive than controls to the effects
of phase (first visit effect, P 5.04 for patients, P 5.65
for controls). As seen in Figure 3, patients had elevated
ACTH levels in Phase 1 but not in Phase 2, whereas
control subjects’ ACTH did not change across phases.
In Phase 2, patients showed significantly elevated
ACTH levels only during their first visit (placebo day
peak, P 5.03). ‘‘Baseline’’ ACTH prior to pentagastrin
was higher in Phase 1 than in Phase 2 for all subjects
(P 5.0001).
Commentary. Prechallenge ACTH levels were
higher when the challenge agent was given in the
single-visit phase and subjects knew for certain that
they would receive the drug, compared to the two-visit
phase in which the drug was given only after a placebo
day visit and subjects did not know for certain whether
they would receive the drug. This suggests that
anticipatory expectancies influenced HPA axis activity
in all subjects. Patients with panic disorder, however,
appeared more sensitive to a first-visit effect on
ACTH, showing significantly greater effects of phase
and elevations on first visit to the study setting
regardless of phase. Patients with panic disorder thus
appeared more sensitive to pentagastrin in Phase 1, but
this abnormality disappeared when they were desensi-
tized to the first-visit effect. Their sensitivity was to the
experimental paradigm itself, not to the challenge
agent. Patients with panic disorder thus have normal
HPA response to the pharmacological effects of penta-
gastrin (normal CCK-B receptor sensitivity) but heigh-
tened sensitivity to paradigm factors (e.g., novelty).
PENTAGASTRIN STUDY 2
Design. This study [Abelson et al., 2005] was
identical to Phase 2 of Pentagastrin Study 1 except for
the addition of random assignment to receive SI or the
same CI used in the doxapram study (described earlier).
Cortisol and ACTH were measured before (30 and
2 minutes) and after intravenous injection of placebo
or pentagastrin (0.6 mg/kg). Postinjection samples were
obtained at 13, 5, 10, 20, 30, 45, and 60 minutes.
All subjects (14 patients, 14 controls) received placebo
on their first visit and pentagastrin on their second. SI
or CI was given 2.5 hours before pentagastrin injection.
Results. Data are presented in Figure 4. Patients
were more symptomatically reactive to pentagastrin
than controls when they received SI, but the CI
completely normalized the patients’ exaggerated anxi-
ety response (Fig. 4A: SI patients 4 CI patients,
P 5.003; SI patients 4 controls, P 5.05; CI patients 5
controls). The CI differentially impacted patient and
control ACTH responses to pentagastrin (Fig. 4B:
diagnosis  instruction interaction, P 5.05), signifi-
cantly reducing it in patients (CIoSI, P 5.03), but not
in controls (CI 5 SI, P 5.49). The CI also differentially
impacted patient and control ACTH responses on
placebo day (Fig. 4C: diagnosis  instruction interac-
tion, P 5.03). SI patients had a significant rise in
ACTH from initial, baseline levels on placebo day
(P 5.02), but CI patients did not show a similar rise
(P 5.37). Controls showed the opposite pattern, with a
significant rise in ACTH for those receiving the CI
(P 5.01) but not for those receiving the SI (P 5.65).
Figure 3. ACTH levels (M7SE) in panic patients and controls,
before and after pentagastrin or placebo injection. In Phase 1,
subjects received pentagastrin during their first visit to the
research center (no placebo given). In Phase 2, subjects received
placebo during their first visit to the research center and
pentagastrin during a second visit.
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Commentary. Patients had exaggerated ACTH
responses to placebo and exaggerated anxiety and
ACTH responses to pentagastrin, but all of these
responses were normal in patients with panic disorder
who received the CI. This suggests that their HPA axes
were overreacting to the experimental paradigm, and
that his reactivity could be ameliorated by a brief CI.
This is consistent with the hypothesis that HPA axis
abnormalities in patients with panic disorder may
involve heightened sensitivity to contextual factors,
and suggests that this hypersensitivity can be blocked
through cognitive preparation that targets factors
known to be salient to the HPA axis (novelty, control,
and access to coping responses).
DISCUSSION
These results suggest that experimental contexts that
are novel, threatening, or uncontrollable (e.g., phar-
macological challenge paradigms) can raise HPA
activity above ‘‘basal’’ levels in all subjects, including
healthy controls; but it would appear that panic
patients may be more sensitive to these contextual
factors. This hypersensitivity may account for HPA axis
abnormalities reported in the panic disorder literature.
Our findings of a normal ACTH response to CRH
after an extremely prolonged period of ‘‘basal state’’
monitoring is consistent with this interpretation,
because it suggests that when sufficiently desensitized
to contextual factors, patients with panic disorder
do not show evidence of central HPA axis overdrive.
The blunted response to CRH reported by Roy-Byrne
et al. [1986] is also consistent with this interpretation,
because the short accommodation period used in that
study was associated with elevated pre-CRH cortisol,
likely due to unresolved hyperreactivity to entry into
the challenge paradigm, and the elevated ‘‘baseline’’
cortisol can be expected to blunt the subsequent
ACTH response to CRH. If so, then psychobiological
overreactivity to novelty can account for an ‘‘abnormal’’
response to a biological probe like CRH. Contextual
differences between paradigms (e.g., length of accom-
modation period) could produce inconsistencies across
studies.
In our pentagastrin model, we saw an initial
suggestion of exaggerated ACTH response to the
CCK-B agonist, but this ‘‘abnormality’’ appears to have
been created by the additive effects of pharmacological
activation and novel exposure to a challenge paradigm.
When novelty effects were diminished by prior
exposure to the challenge context, the HPA responses
of patients with panic disorder were normal. Exagger-
ated HPA activity in these patients in this model
could also be normalized by a brief CI that enhanced
familiarity with expectable sensations, coached
subjects in cognitive coping, and provided an illusion
of control.
The elevated nocturnal levels of cortisol seen in our
24-hour study [Abelson and Curtis, 1996a] seem more
difficult to attribute to hypersensitivity to contextual
factors; however, such sensitivity could readily produce
nocturnal awakenings in the laboratory setting, and
such awakenings can trigger cortisol release (Van
Cauter, personal communication, 2005) and elevate
overnight levels. The linkage between these overnight
levels and later disability suggests trait factors at work.
Animal work has shown that both developmental and
genetic factors can produce chronic overreactivity to
environmental novelty, physiologically and behavio-
rally [Caldji et al., 1998, 2000; Suomi, 1997]. Sensitized
animals have normal baseline HPA axis function but
heightened reactivity, and are behaviorally dysfunc-
tional throughout their lives. Patients with panic
disorder may have a similar, trait-based dysregulation,
producing heightened reactivity to novelty that has
both biological and behavioral repercussions—seen in
enhanced HPA axis reactivity to novel experimental
contexts, and elevated cortisol in some paradigms, and
in heightened fear of panic in unfamiliar environments,
leading to more avoidance and reduced functional
capacity. Such a trait could therefore be the mediating
variable creating the long-term link we saw in the
24-hour study between cortisol levels at entry and
disability levels 2 years later.










































































Figure 4. Symptom and ACTH (M7SE) responses (peak minus baseline) to pentagastrin or placebo in patients with panic disorder and
matched controls, receiving either SI or a CI designed to reduce the stressfulness of the procedures: (A) Subjective anxious distress
responses to pentagastrin; (B) ACTH responses to pentagastrin; (C) ACTH responses to placebo (first visit).
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A summary of HPA axis findings in panic, published
by others, is presented in Table 1. It is difficult to
evaluate these findings fully in light of the hypothesis
presented here, because our own data show that what is
said to patients with panic disorder in preparing them
for their experiences within a study can make a
significant difference in their HPA responses. Most
reports provide little information on subject prepara-
tion procedures, and many do not provide details about
accommodation periods and prior exposure to experi-
mental contexts. As a result, study differences in
novelty or familiarity, perceived controllability, and
social support or assistance in coping are not readily
discerned.
The findings in Table 1 highlight a failure to
consistently find HPA axis abnormalities in panic.
It is clear that panic attacks can occur without acute
elevation in cortisol levels [Abelson et al., 1996;
Cameron et al., 1987; Hollander et al., 1989; Kellner
et al., 1995; Peskind et al., 1998]. When exaggerated
responses have been seen in laboratory panic models,
these could reflect sensitivity to the challenge para-
digms themselves rather than sensitivity to the provo-
cative agents used or correlates of the panic attacks
generated. For example, exaggerated cortisol responses
to yohimbine have been reported in patients with panic
disorder [Gurguis et al., 1997]. However, in this study,
half of the subjects received yohimbine on a first visit to
the study setting and half received placebo. Analyses to
detect a first-visit effect, as seen in our pentagastrin
study, are not reported. The elevations in cortisol
reported were fairly small (5 mg/dl) and significant
findings involved total postinjection secretion, as in our
pentagastrin study. These could be due to those
subjects who received yohimbine on a first visit, which
combines a challenge agent effect and a novelty effect.
Larger cortisol response elevations (15 mg/dl) relative
to controls were seen in a fenfluramine challenge
[Targum and Marshall, 1989], but in this study, seven
of the nine patients with panic disorder received the
challenge on a first visit to the laboratory. Again,
heightened HPA axis activity in the patients with panic
disorder could be due to a first-visit sensitivity that
amplifies a normal sensitivity to the provocative agent.
Pharmacological probes of intrinsic, central drive,
and feedback inhibition should be less susceptible to
acute reactivity effects. However, as noted earlier, even
the CRH challenge can be affected by ‘‘baseline’’
reactivity, if feedback inhibition is intact. The DST
probes feedback circuits and should be relatively
insensitive to acute reactivity effects. The lack of
consistently exaggerated escape from suppression or
hypersuppression on the DST suggests that inhibitory
components are intact in panic. When abnormalities
have been detected on the DST, they appear to be
associated with the presence of agoraphobia [Westberg
et al., 1991] or severity of depression [Coryell et al.,
1989] rather than the severity of panic. DST non-
suppression in patients with panic disorder entering a
treatment study predicts greater disability at 3-year
follow-up [Coryell et al., 1991], which is consistent
with our report that elevated 24-hour cortisol levels
at treatment entry predict follow-up disability [Abelson
and Curtis, 1996b]. These HPA axis abnormalities may
be marking a trait that is not disease specific but that
enhances general vulnerability to psychopathology,
perhaps increasing risk of comorbidity and functional
impairment. Such a trait could involve heightened
reactivity to or reduced ability to cope with environ-
mental novelty. Heightened cortisol reactivity to a




No or inconsistent cortisol response with laboratory-
induced panic attacks
Charney et al., 1985 (caffeine); Liebowitz et al., 1985; Levin
et al., 1987; Seier et al., 1997; Peskind et al., 1998 (lactate);
Sinha et al., 1999; van Duinen et al., 2004; (CO2) Peskind
et al., 1998 (hypertonic saline)
Increased cortisol response to challenge Woods et al., 1988 (CO2); Gurguis et al., 1997; Charney et al.,
1987 (yohimbine); Targum and Marshall, 1989
(fenfluramine); Leyton et al., 1996 (psychological stress)
CRH Blunted ACTH response Roy-Byrne et al., 1986; Holsboer et al., 1987
Normal or increased ACTH response Rapaport et al., 1989; Brambilla et al., 1992; Schreiber et al.,
1996
Change in ACTH/cortisol ratio Brambilla et al., 1992
DST Normal or slightly elevated rate of non-suppression Curtis et al., 1982; Lieberman et al., 1983; Sheehan et al., 1983;
Goldstein et al., 1987
Elevated nonsuppression rate with repeat testing, linked to
severity of depression
Coryell et al., 1989
Basal studies Normal UFC (in uncomplicated panic) Uhde et al., 1988; Kathol et al., 1988
Elevated ACTH increased afternoon or nocturnal cortisol Brambilla et al., 1992 Goldstein et al., 1987; Bandelow et al.,
1997; Bandelow et al., 2000b
‘‘Natural’’ panic Increased cortisol Bandelow et al., 2000a
Inconsistent response Cameron et al., 1987; Woods et al., 1987
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novel psychological challenge has been documented in
one study of patients with panic disorder [Leyton et al.,
1996]. The patients in this study were in remission
at the time of study, supporting the idea that HPA axis
reactivity in panic may mark a trait that is not directly
linked to patients’ panic disorder symptoms.
Some findings in the panic–HPA literature are
difficult to reconcile with the hypothesis proposed
here. For example, Goldstein et al. [1987] found
elevated afternoon cortisol levels in patients with panic
disorder, even though DST results in these same
patients were normal. Their procedure involved con-
tinuous blood extraction through an intravenous
catheter over a 3-hour period, which should provide
a better measure of true basal activity than levels before
a challenge. However, our data suggest the even subtle
aspects of the experimental context, and preparation
for it, can impact the HPA axis in patients with
panic disorder. Their continuous extraction procedure
may be sufficiently novel to elicit an exaggerated
response in patients with panic disorder relative to
controls, so this ‘‘basal’’ abnormality could in fact
reflect a reactivity effect.
The Von Bardeleben and Holsboer [1988] data
showing blunted ACTH responses to CRH in patients
with panic disorder even after a prolonged baseline
(6 hours) are harder to reconcile. The prolonged
baseline resulted in normal pre-CRH cortisol levels,
similar to the normal pre-CRH baselines seen in our
24-hour study [Abelson and Curtis, 1996a], so feedback
inhibition from pre-CRH cortisol elevations cannot
explain the ACTH blunting. The report from this
group makes it clear that they carefully controlled
‘‘exogenous stressors,’’ because they recognized the
excessive responsivity of patients with panic disorder to
such stimuli [Von Bardeleben and Holsboer, 1988].
This study therefore provides the strongest evidence
for intrinsically elevated central drive in the HPA axes
of patients with panic disorder. However, it is a single
study with a small sample, and full description of the
patients with panic disorder and their comorbidities are
not provided in two different publications of these data
[Holsboer et al., 1987; Von Bardeleben and Holsboer,
1988]. The authors themselves conclude that patients
with panic disorder do not show the same kind of
clear, centrally driven overactivity of the HPA axis
seen in depression, but instead show a less strictly
organized and less stable endocrine response pattern
[Von Bardeleben and Holsboer, 1988].
The finding of abnormal cortisol responses to a
combined dexamethasone–CRH test also supports a
central dysregulation of the HPA axis in panic
[Schreiber et al., 1996]. However, this study also
compared patients with panic disorder and those with
depression, and showed that depression was associated
with abnormal ACTH responses to the test, whereas
patients with panic disorder had normal ACTH
responses and only differed from controls in cortisol
responses. The cortisol responses, however, were
significantly affected by sex, and the panic group was
predominantly female, whereas the control group was
predominantly male. The only other HPA abnormality
in the patients with panic disorder was an elevated
‘‘baseline’’ cortisol, but cortisol elevations with only a
30-minute accommodation following venipuncture and
immediately preceding a pharmacological challenge are
consistent with our environmental reactivity hypothesis.
HPA studies that use urinary or salivary collections
allow assessment in more naturalistic settings and may
avoid the impact of the more invasive procedures
needed to obtain plasma measures. Twenty-four hour
urinary free cortisol (UFC) has been shown to be
normal in panic disorder [Uhde et al., 1988], or
elevated only in the presence of depression or
agoraphobia [Kathol et al., 1988; Lopez et al., 1990].
Bandelow et al. [1997, 2000b], on the other hand,
report elevated nocturnal urinary secretion of cortisol
in patients with panic disorder over multiple nights
measured at home, which seems unlikely to be
impacted by reactivity to novelty or contextual
variables. However, Bandelow et al. [1997] note that
nocturnal awakenings could explain this elevation.
Using a novel design, this group also reports elevated
cortisol levels in saliva samples obtained during
naturally occurring panic attacks [Bandelow et al.,
2000a]. The elevations reported were in comparison
to samples obtained 24 hours later, when an attack was
not occurring. These data may suggest that cortisol is
elevated during naturalistic attacks, in contrast to
laboratory attacks. However, elevations were already
present in the first sample taken, immediately after
attack onset, and may have been present even before-
hand. In this naturalistic model, a cortisol ‘‘response’’
may not have been seen if levels during the attack were
compared to those immediately before, as is done in
the laboratory models. In the laboratory models,
‘‘elevations’’ would likely also be seen if the ‘‘baseline’’
used was cortisol measured 24 hours later at home.
In at least one laboratory model, higher cortisol before
challenge increases the likelihood of a panic response
to the challenge [Coplan et al., 1998]. It may be that
the greater subjects’ novelty sensitivity, the higher their
‘‘baseline’’ cortisol in a challenge paradigm, and the
greater their likelihood of panic. The Bandelow data
may reflect a similar process, in that prepanic cortisol
levels may have been elevated, and the factors
contributing to this elevation (e.g., hyperreactivity to
a perceived, actual, or anticipated environmental
challenge) may have provided the trigger for the
subsequent attack.
Our conclusion is that most of the HPA axis
disturbances reported in panic could be due to
heightened sensitivity to environmental cues that are
salient to this neuroendocrine stress system. Animal
literature suggests that novelty and threat are salient
to the HPA axis, particularly in the absence of control,
social support, or meaningful coping response. These
are precisely the factors that were addressed by the
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cognitive intervention that appeared to ‘‘correct’’ HPA
axis abnormalities in panic in our pentagastrin model.
A correctable sensitivity to one or more of these factors
may explain the HPA axis abnormalities that have been
reported in patients with panic disorder.
The animal literature suggests that the effects of
‘‘processive’’ stimuli such as novelty on the HPA axis
reach the hypothalamus via ‘‘higher’’ level cortical and
limbic circuits that allow interpretation of their
meaning and salience, influenced by past experience
[Herman and Cullinan, 1997]. In contrast to systemic
stressors such as hypoxia, HPA responses to these
behavioral stressors are altered by lesions in cortical/
limbic regions [e.g., prefrontal cortex, amygdala, and
hippocampus; Herman and Cullinan, 1997]. If heigh-
tened reactivity to some aspects of experimental
contexts provides a parsimonious explanation for
HPA axis abnormalities in patients with panic disorder,
the animal literature would point us toward the
cortical/limbic pathways that provide modulatory input
to the hypothalamus in our search for the source of this
dysregulation.
Animal models have focused attention on the
amygdala as a potential site of dysregulation in
anxiety disorders [Shekhar et al., 1999], and hyper-
activity within the amygdala could play a role in panic.
The amygdala can also influence hypothalamic activity
and cortisol release [Rubin et al., 1966]. Excessive
reactivity of the amygdala could contribute to panic
and lead to enhanced HPA axis reactivity. How-
ever, amydgalar output is a consequence of complex,
interacting activating and inhibitory inputs from
multiple regions, including cortex [Shekhar et al.,
1999], so enhanced amydgalar reactivity could result
from dysregulation within cortical/limbic modu-
latory circuits.
In our work, both prior experience in the laboratory
setting and verbal/cognitive manipulation were able to
reduce HPA axis hyperreactivity in patients with panic
disorder. These effects must also involve modulation of
hypothalamic activity via ‘‘higher’’ brain circuits that
somehow determine the salience of past experience or
cognitive inputs to current challenges. Medial pre-
frontal cortex is a strong candidate for inclusion in such
a modulatory circuit, since it is known to process
emotional salience and to provide inhibitory input to
the HPA axis [Diorio et al., 1993]. Such higher level
inhibitory pathways may be a particularly fruitful place
to look for the source of the HPA axis dysregulation
seen in panic disorder. Such circuits may be of general
relevance to the pathophysiology of this disorder. We
propose a speculative but testable specific hypothesis—
that HPA abnormalities in panic are due to dysregula-
tion in suprahypothalamic circuits and may involve a
specific hypersensitivity to novelty cues. Future work
should directly test this hypothesis.
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